• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Allakos Inc. (Amendment)

    2/2/24 12:31:26 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLK alert in real time by email
    SC 13D/A 1 d700021dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13D/A

    (Amendment No. 4)

    Under the Securities Exchange Act of 1934

     

     

    ALLAKOS INC.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    01671P100

    (CUSIP Number)

    John P. McKearn

    101 S. Hanley Road, Suite 1850

    St. Louis, MO 63105

    (314) 726-6700

    With copy to:

    Gloria M. Skigen, Esq.

    Holland & Knight LLP

    One Stamford Plaza 263 Tresser Boulevard Suite 1400

    Stamford, CT 06901

    (203) 905-4526

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    January 16, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 01671P100   13D/A   Page 2 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest Venture Fund II, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    The percentage set forth in row (13) is based on the 87,476,338 shares of common stock, par value $0.001 per share (“Common Stock”), of Allakos Inc., a Delaware corporation (the “Issuer”), reported by the Issuer to be outstanding as of November 7, 2023 on the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission (“SEC”) on November 13, 2023.


    CUSIP No. 01671P100   13D/A   Page 3 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest Venture Fund II (Ohio), L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 01671P100   13D/A   Page 4 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest Venture Partners II (Ohio), LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0(2)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0(2)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0(2)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     OO

     

    (2)

    Represents shares of Common Stock owned by RiverVest Venture Fund II (Ohio), L.P., a Delaware limited partnership (“RiverVest II (Ohio)”). RiverVest Venture Partners II (Ohio), LLC, a Delaware limited liability company (“RiverVest Partners II (Ohio)”), is the general partner of RiverVest II (Ohio).


    CUSIP No. 01671P100   13D/A   Page 5 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest Venture Partners II, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0(3)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0(3)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0(3)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     PN

     

    (3)

    Represents shares of Common Stock owned by RiverVest Venture Fund II, L.P., a Delaware limited partnership (“RiverVest II”), and shares of Common Stock owned by RiverVest II (Ohio). RiverVest Venture Partners II, L.P., a Delaware limited partnership (“RiverVest Partners II”), is the general partner of RiverVest II and the sole member of RiverVest Partners II (Ohio), which is the general partner of RiverVest II (Ohio).


    CUSIP No. 01671P100   13D/A   Page 6 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest Venture Partners II, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0(4)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0(4)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0(4)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     OO

     

    (4)

    Represents shares of Common Stock owned by RiverVest II and shares of Common Stock owned by RiverVest II (Ohio). RiverVest Venture Partners II, LLC, a Delaware limited liability company, is the general partner of RiverVest Partners II, which is (a) the general partner of RiverVest II and (b) the sole member of RiverVest Partners II (Ohio), which is the general partner of RiverVest II (Ohio).


    CUSIP No. 01671P100   13D/A   Page 7 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest Venture Fund III, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 01671P100   13D/A   Page 8 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest Venture Fund III (Ohio), L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 01671P100   13D/A   Page 9 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest Venture Partners III (Ohio), LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0(5)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0(5)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0(5)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     OO

     

    (5)

    Represents shares of Common Stock owned by RiverVest Venture Fund III (Ohio), L.P., a Delaware limited partnership (“RiverVest III (Ohio)”). RiverVest Venture Partners III (Ohio), LLC, a Delaware limited liability company (“RiverVest Partners III (Ohio)”), is the general partner of RiverVest III (Ohio).


    CUSIP No. 01671P100   13D/A   Page 10 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest Venture Partners III, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0(6)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0(6)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0(6)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     PN

     

    (6)

    Represents shares of Common Stock owned by RiverVest Venture Fund III, L.P., a Delaware limited partnership (“RiverVest III”), and shares of Common Stock owned by RiverVest III (Ohio). RiverVest Venture Partners III, L.P., a Delaware limited partnership (“RiverVest Partners III”), is the general partner of RiverVest III and the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio).


    CUSIP No. 01671P100   13D/A   Page 11 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest Venture Partners III, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0(7)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0(7)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0(7)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     OO

     

    (7)

    Represents shares of Common Stock owned by RiverVest III and shares of Common Stock owned by RiverVest III (Ohio). RiverVest Venture Partners III, LLC, a Delaware limited liability company, is the general partner of RiverVest Partners III, which is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio).


    CUSIP No. 01671P100   13D/A   Page 12 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     3x5 RiverVest Fund II, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 01671P100   13D/A   Page 13 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     3x5 RiverVest Fund II-B, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     PN


    CUSIP No. 01671P100   13D/A   Page 14 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     3x5 RiverVest Partners II, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0(8)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0(8)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0(8)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     OO

     

    (8)

    Represents shares of Common Stock owned by 3x5 RiverVest Fund II, L.P., a Delaware limited partnership (“3x5 RiverVest II”), and shares of Common Stock owned by 3x5 RiverVest Fund II-B, L.P., a Delaware limited partnership (“3x5 RiverVest II-B”). 3x5 RiverVest Partners II, LLC, a Delaware limited liability company (“3x5 RiverVest Partners”), is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B.


    CUSIP No. 01671P100   13D/A   Page 15 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest 3x5 Managers II, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0(9)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0(9)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0(9)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     PN

     

    (9)

    Represents shares of Common Stock owned by 3x5 RiverVest II and shares of Common Stock owned by 3x5 RiverVest II-B. RiverVest 3x5 Managers II, L.P., a Delaware limited partnership (“RiverVest 3x5 Managers”), is one of two members of 3x5 RiverVest Partners, which is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B.


    CUSIP No. 01671P100   13D/A   Page 16 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     RiverVest 3x5 Managers II, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware, USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     0

        8   

     SHARED VOTING POWER

     

     0(10)

        9   

     SOLE DISPOSITIVE POWER

     

     0

       10   

     SHARED DISPOSITIVE POWER

     

     0(10)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0(10)

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.0%(1)

    14  

     TYPE OF REPORTING PERSON

     

     OO

     

    (10)

    Represents shares of Common Stock owned by 3x5 RiverVest II and shares of Common Stock owned by 3x5 RiverVest II-B. RiverVest 3x5 Managers II, LLC, a Delaware limited liability company (“RiverVest 3x5 Managers II”), is the general partner of RiverVest 3x5 Managers, which is one of two members of 3x5 RiverVest Partners. 3x5 RiverVest Partners is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B.


    CUSIP No. 01671P100   13D/A   Page 17 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     John P. McKearn, Ph.D.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     108,159(11)

        8   

     SHARED VOTING POWER

     

     0(12)

        9   

     SOLE DISPOSITIVE POWER

     

     108,159(11)

       10   

     SHARED DISPOSITIVE POWER

     

     0(12)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     108,159

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.2%(1)

    14  

     TYPE OF REPORTING PERSON

     

     IN

     

    (11)

    Represents 108,159 shares of Common Stock held directly by Dr. McKearn.

    (12)

    Represents shares of Common Stock owned by RiverVest II, shares of Common Stock owned by RiverVest II (Ohio), shares of Common Stock owned by RiverVest III, shares of Common Stock owned by RiverVest III (Ohio), shares of Common Stock owned by 3x5 RiverVest II and shares of Common Stock owned by 3x5 RiverVest II-B.

    Dr. McKearn is an authorized person of RiverVest Venture Partners II, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners II. RiverVest Partners II is (a) the general partner of RiverVest II and (b) the sole member of RiverVest Partners II (Ohio), which is the general partner of RiverVest II (Ohio).

    Dr. McKearn is a member of RiverVest Venture Partners III, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio).

    Dr. McKearn is a member of RiverVest 3x5 Managers II, the general partner of RiverVest 3x5 Managers, which in turn is one of two members of 3x5 RiverVest Partners. 3x5 RiverVest Partners is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B.


    CUSIP No. 01671P100   13D/A   Page 18 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     Jay Schmelter

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     16,610(13)

        8   

     SHARED VOTING POWER

     

     0(14)

        9   

     SOLE DISPOSITIVE POWER

     

     16,610(13)

       10   

     SHARED DISPOSITIVE POWER

     

     0(14)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     16,610

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.02%(1)

    14  

     TYPE OF REPORTING PERSON

     

     IN

     

    (13)

    Represents 11,766 shares of Common Stock held directly, 1,868 shares of Common Stock owned by RiverVest Venture Management LLC Profit Sharing Plan FBO Jay W. Schmelter, 1,488 shares of Common Stock owned by the Schmelter Family Trust dated 5/2/19 and 1,488 shares of Common Stock owned by the Schmelter Family Trust #2 dated 9/30/2019.

    (14)

    Represents shares of Common Stock owned by RiverVest II, shares of Common Stock owned by RiverVest II (Ohio), shares of Common Stock owned by RiverVest III, shares of Common Stock owned by RiverVest III (Ohio), shares of Common Stock owned by 3x5 RiverVest II and shares of Common Stock owned by 3x5 RiverVest II-B.

    Mr. Schmelter is a member of RiverVest Venture Partners II, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners II. RiverVest Partners II is (a) the general partner of RiverVest II and (b) the sole member of RiverVest Partners II (Ohio), which is the general partner of RiverVest II (Ohio).

    Mr. Schmelter is a member of RiverVest Venture Partners III, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio).

    Mr. Schmelter is a member of RiverVest 3x5 Managers II, the general partner of RiverVest 3x5 Managers, which in turn is one of two members of 3x5 RiverVest Partners. 3x5 RiverVest Partners is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B.


    CUSIP No. 01671P100   13D/A   Page 19 of 26 Pages

     

     1   

     NAME OF REPORTING PERSON

     I.R.S. IDENTIFICATION NO. (ENTITIES ONLY)

     

     Thomas C. Melzer

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     AF

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     USA

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     21,476(15)

        8   

     SHARED VOTING POWER

     

     0(16)

        9   

     SOLE DISPOSITIVE POWER

     

     21,476(15)

       10   

     SHARED DISPOSITIVE POWER

     

     0(16)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     21,476

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     0.03%(1)

    14  

     TYPE OF REPORTING PERSON

     

     IN

     

    (15)

    Includes 10,738 shares of Common Stock owned by the Thomas C. Melzer Revocable Trust dtd 4/4/2002 and 10,738 shares of Common Stock owned by Melzer Family Trust dated 11/9/2006.

    (16)

    Represents shares of Common Stock owned by RiverVest II, shares of Common Stock owned by RiverVest II (Ohio), shares of Common Stock owned by RiverVest III, shares of Common Stock owned by RiverVest III (Ohio), shares of Common Stock owned by 3x5 RiverVest II and shares of Common Stock owned by 3x5 RiverVest II-B.

    Mr. Melzer is a member of RiverVest Venture Partners II, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners II. RiverVest Partners II is (a) the general partner of RiverVest II and (b) the sole member of RiverVest Partners II (Ohio), which is the general partner of RiverVest II (Ohio).

    Mr. Melzer is a member of RiverVest Venture Partners III, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio).

    Mr. Melzer is a member of RiverVest 3x5 Managers II, the general partner of RiverVest 3x5 Managers, which in turn is one of two members of 3x5 RiverVest Partners. 3x5 RiverVest Partners is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B.


    CUSIP No. 01671P100   13D/A   Page 20 of 26 Pages

     

    Schedule 13D/A

    Pursuant to Rule 13d-2 of Regulation 13D-G of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended, the undersigned hereby amends the statement on Schedule 13D dated September 10, 2018, as amended on May 26, 2020, as further amended on January 8, 2021, as further amended on February 22, 2021 (the “Schedule 13D”). This Statement constitutes Amendment No. 4 to the Schedule 13D. Unless otherwise indicated herein, there are no material changes to the information set forth in the Schedule 13D.

    Except as otherwise provided herein, each Item of the Schedule 13D remains unchanged.

    Item 1. Security and Issuer.

    No change.

    Item 2. Identity and Background.

    No change.

    Item 3. Source and Amount of Funds or Other Consideration.

    The following table indicates sales effected during the preceding 60 days by RiverVest II, RiverVest II (Ohio), RiverVest III, RiverVest III (Ohio), 3x5 RiverVest II, 3x5 RiverVest II-B on January 16, 2024 through open market transactions:

     

    Entity

       Shares      Price Per Share  

    RiverVest Venture Fund II, L.P.

         694,669      $ 1.1741  

    RiverVest Venture Fund II (Ohio), L.P.

         188,685      $ 1.1741  

    RiverVest Venture Fund III, L.P.

         2,341,594      $ 1.1741  

    RiverVest Venture Fund III (Ohio), L.P.

         124,275      $ 1.1741  

    3x5 RiverVest Fund II, L.P.

         1,483,103      $ 1.1741  

    3x5 RiverVest Fund II-B, L.P.

         55,606      $ 1.1741  

    Item 4. Purpose of the Transaction.

    No change.


    CUSIP No. 01671P100   13D/A   Page 21 of 26 Pages

     

    Item 5. Interest in Securities of the Issuer.

    (a) and (b) 

     

    Entity or Individual

       Shares
    Held
    Directly
         Sole
    Voting
    Power
         Shared
    Voting
    Power
         Sole
    Dispositive
    Power
         Shared
    Dispositive
    Power
         Beneficial
    Ownership
         Percentage
    of Class(*)
     

    RiverVest Venture Fund II, L.P.

         0        0        0        0        0        0        0 % 

    RiverVest Venture Fund II (Ohio), L.P.

         0        0        0        0        0        0        0 % 

    RiverVest Venture Partners II (Ohio), LLC(1)

         0        0        0        0        0        0        0 % 

    RiverVest Venture Partners II, L.P.(2)

         0        0        0        0        0        0        0 % 

    RiverVest Venture Partners II, LLC(3)

         0        0        0        0        0        0        0 % 

    RiverVest Venture Fund III, L.P.

         0        0        0        0        0        0        0 % 

    RiverVest Venture Fund III (Ohio), L.P.

         0        0        0        0        0        0        0 % 

    RiverVest Venture Partners III (Ohio), LLC(4)

         0        0        0        0        0        0        0 % 

    RiverVest Venture Partners III, L.P.(5)

         0        0        0        0        0        0        0 % 

    RiverVest Venture Partners III, LLC(6)

         0        0        0        0        0        0        0 % 

    3x5 RiverVest Fund II, L.P.

         0        0        0        0        0        0        0 % 

    3x5 RiverVest Fund II-B, L.P.

         0        0        0        0        0        0        0 % 

    3x5 RiverVest Partners II, LLC(7)

         0        0        0        0        0        0        0 % 

    RiverVest 3x5 Managers II, L.P.(8)

         0        0        0        0        0        0        0 % 

    RiverVest 3x5 Managers II, LLC(9)

         0        0        0        0        0        0        0 % 

    John P. McKearn, Ph.D.(10)

         108,159        108,159        0        108,159        0        108,159        0.1 % 

    Jay Schmelter(11)

         16,610        16,610        0        16,610        0        16,610        0.02 % 

    Thomas C. Melzer(12)

         21,476        21,476        0        21,476        0        21,476        0.03 % 

     


    CUSIP No. 01671P100   13D/A   Page 22 of 26 Pages

     

      (*)

    Based on the 87,476,338 shares of Common Stock reported by the Issuer to be outstanding as of November 7, 2023 on the Issuer’s Form 10-Q, filed with the SEC on November 13, 2023.

     

    (1)

    RiverVest Partners II (Ohio), as the general partner of RiverVest II (Ohio), may be deemed to beneficially own the shares of Common Stock owned by RiverVest II (Ohio).

     

    (2)

    RiverVest Partners II is the general partner of RiverVest II and the sole member of RiverVest Partners II (Ohio), which is the general partner of RiverVest II (Ohio), and as a result, may be deemed to beneficially own the shares of Common Stock owned by RiverVest II and the shares of Common Stock owned by RiverVest II (Ohio).

     

    (3)

    RiverVest Venture Partners II, LLC, a Delaware limited liability company, is the general partner of RiverVest Partners II, which is (a) the general partner of RiverVest II and (b) the sole member of RiverVest Partners II (Ohio), which is the general partner of RiverVest II (Ohio), and as a result, may be deemed to beneficially own the shares of Common Stock owned by RiverVest II and the shares of Common Stock owned by RiverVest II (Ohio).

     

    (4)

    RiverVest Partners III (Ohio) is the general partner of RiverVest III (Ohio), and as a result, may be deemed to beneficially own the shares of Common Stock owned by RiverVest III (Ohio).

     

    (5)

    RiverVest Partners III is the general partner of RiverVest III and the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio), and as a result, may be deemed to beneficially own the shares of Common Stock owned by RiverVest III and the shares of Common Stock owned by RiverVest III (Ohio).

     

    (6)

    RiverVest Venture Partners III, LLC, a Delaware limited liability company, is the general partner of RiverVest Partners III, which is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio), and as a result, may be deemed to beneficially own the shares of Common Stock owned by RiverVest III and the shares of Common Stock owned by RiverVest III (Ohio).

     

    (7)

    3x5 RiverVest Partners is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B, and as a result, may be deemed to beneficially own the shares of Common Stock owned by 3x5 RiverVest II and the shares of Common Stock owned by 3x5 RiverVest II-B.

     

    (8)

    RiverVest 3x5 Managers is one of two members of 3x5 RiverVest Partners, which is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B, and as a result, may be deemed to beneficially own the shares of Common Stock owned by 3x5 RiverVest II and the shares of Common Stock owned by 3x5 RiverVest II-B.

     

    (9)

    RiverVest 3x5 Managers II is the general partner of RiverVest 3x5 Managers, which is one of two members of 3x5 RiverVest Partners. 3x5 RiverVest Partners is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B. As a result, RiverVest 3x5 Managers II may be deemed to beneficially own the shares of Common Stock owned by 3x5 RiverVest II and the shares of Common Stock owned by 3x5 RiverVest II-B.

     

    (10)

    Dr. McKearn is an authorized person of RiverVest Venture Partners II, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners II. RiverVest Partners II is (a) the general partner of RiverVest II and (b) the sole member of RiverVest Partners II (Ohio), which is the general partner of RiverVest II (Ohio). As a result, Dr. McKearn may be deemed to beneficially own the shares of Common Stock owned by RiverVest II and the shares of Common Stock owned by RiverVest II (Ohio).

    Dr. McKearn is a member of RiverVest Venture Partners III, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). As a result, Dr. McKearn may be deemed to beneficially own the shares of Common Stock owned by RiverVest III and the shares of Common Stock owned by RiverVest III (Ohio).

    Dr. McKearn is a member of RiverVest 3x5 Managers II, the general partner of RiverVest 3x5 Managers, which in turn is one of two members of 3x5 RiverVest Partners. 3x5 RiverVest Partners is the general partner of 3x5 RiverVest II and 3x5

    RiverVest II-B. As a result, Dr. McKearn may be deemed to beneficially own the shares of Common Stock owned by 3x5 RiverVest II and the shares of Common Stock owned by 3x5 RiverVest II-B.


    CUSIP No. 01671P100   13D/A   Page 23 of 26 Pages

     

    Represents 168,590 fully vested options granted to Dr. McKearn by the Issuer as reported by the Issuer on the Issuer’s Proxy Statement, filed with the SEC on April 20, 2023.

     

    (11)

    Mr. Schmelter is a member of RiverVest Venture Partners II, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners II. RiverVest Partners II is (a) the general partner of RiverVest II and (b) the sole member of RiverVest Partners II (Ohio), which is the general partner of RiverVest II (Ohio). As a result, Mr. Schmelter may be deemed to beneficially own the shares of Common Stock owned by RiverVest II and the shares of Common Stock owned by RiverVest II (Ohio).

    Mr. Schmelter is a member of RiverVest Venture Partners III, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). As a result, Mr. Schmelter may be deemed to beneficially own the shares of Common Stock owned by RiverVest III and the shares of Common Stock owned by RiverVest III (Ohio).

    Mr. Schmelter is a member of RiverVest 3x5 Managers II, the general partner of RiverVest 3x5 Managers, which in turn is one of two members of 3x5 RiverVest Partners. 3x5 RiverVest Partners is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B. As a result, Mr. Schmelter may be deemed to beneficially own the shares of Common Stock owned by 3x5 RiverVest II and the shares of Common Stock owned by 3x5 RiverVest II-B.

     

    (12)

    Mr. Melzer is a member of RiverVest Venture Partners II, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners II. RiverVest Partners II is (a) the general partner of RiverVest II and (b) the sole member of RiverVest Partners II (Ohio), which is the general partner of RiverVest II (Ohio). As a result, Mr. Melzer may be deemed to beneficially own the shares of Common Stock owned by RiverVest II and the shares of Common Stock owned by RiverVest II (Ohio).

    Mr. Melzer is a member of RiverVest Venture Partners III, LLC, a Delaware limited liability company, which is the general partner of RiverVest Partners III. RiverVest Partners III is (a) the general partner of RiverVest III and (b) the sole member of RiverVest Partners III (Ohio), which is the general partner of RiverVest III (Ohio). As a result, Mr. Melzer may be deemed to beneficially own the shares of Common Stock owned by RiverVest III and the shares of Common Stock owned by RiverVest III (Ohio).

    Mr. Melzer is a member of RiverVest 3x5 Managers II, the general partner of RiverVest 3x5 Managers, which in turn is one of two members of 3x5 RiverVest Partners. 3x5 RiverVest Partners is the general partner of 3x5 RiverVest II and 3x5 RiverVest II-B. As a result, Mr. Melzer may be deemed to beneficially own the shares of Common Stock owned by 3x5 RiverVest II and the shares of Common Stock owned by 3x5 RiverVest II-B.

    By virtue of the relationships described herein, the Reporting Persons may be deemed to constitute a “group” for purposes of Section 13(d)(3) of the Act. The filing of this Statement shall not be construed as an admission that the Reporting Persons are a group, or have agreed to act as a group. Each Reporting Person expressly disclaims beneficial ownership of the securities reported herein, except to the extent such Reporting Person actually exercises voting or dispositive power with respect to such securities.

    (c) Except as set forth herein, none of the Reporting Persons has effected any transactions in the shares of the Issuer’s Common Stock during the last 60 days.

    (d) No change.

    (e) The Reporting Persons ceased to own more than five percent of the outstanding Common Stock on January 16, 2024.


    CUSIP No. 01671P100   13D/A   Page 24 of 26 Pages

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    No change.

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit A:    Joint Filing Agreement, dated September 10, 2018, by and among the Reporting Persons.*

     

    *

    Previously filed.


    CUSIP No. 01671P100   13D/A   Page 25 of 26 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    February 1, 2024

     

    RiverVest Venture Fund II, L.P.

    By: RiverVest Venture Partners II, L.P.,

      its general partner

    By: RiverVest Venture Partners II, LLC,

      its general partner
    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Authorized Person
    RiverVest Venture Partners II (Ohio), LLC

    By: RiverVest Venture Partners II, L.P.,

      its sole member

    By: RiverVest Venture Partners II, LLC,

      its general partner
    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Authorized Person
    RiverVest Venture Partners II, LLC
    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Authorized Person
    RiverVest Venture Fund III (Ohio), L.P.

    By: RiverVest Venture Partners III (Ohio), LLC,

      its general partner

    By: RiverVest Venture Partners III, L.P.,

      its sole member

    By: RiverVest Venture Partners III, LLC,

      its general partner
    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Member
    RiverVest Venture Fund II (Ohio), L.P.

    By: RiverVest Venture Partners II (Ohio), LLC,

      its general partner

    By: RiverVest Venture Partners II, L.P.,

      its sole member

    By: RiverVest Venture Partners II, LLC,

      its general partner
    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Authorized Person
    RiverVest Venture Partners II L.P.

    By: RiverVest Venture Partners II, LLC,

      its general partner
    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Authorized Person
    RiverVest Venture Fund III, L.P.

    By: RiverVest Venture Partners III, L.P.,

      its general partner

    By: RiverVest Venture Partners III, LLC,

      its general partner
    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Member
    RiverVest Venture Partners III (Ohio), LLC

    By: RiverVest Venture Partners III, L.P.,

      its sole member

    By: RiverVest Venture Partners III, LLC,

      its general partner
    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Member
     

     

    [Signature Page of Schedule 13D/A]


    CUSIP No. 01671P100   13D/A   Page 26 of 26 Pages

     

    RiverVest Venture Partners III, L.P.
    By:  

    RiverVest Venture Partners III, LLC,

    its general partner

    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Member
    3x5 RiverVest Fund II, L.P.
    By:  

    3x5 RiverVest Partners II, LLC,

    its general partner

    By:  

    RiverVest 3x5 Managers II, L.P.,

    its member

    By:  

    RiverVest 3x5 Managers II, LLC,

    its general partner

    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Member
    3x5 RiverVest Partners II, LLC
    By:  

    RiverVest 3x5 Managers II, L.P.,

    its member

    By:  

    RiverVest 3x5 Managers II, LLC,

    its general partner

    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Member
    RiverVest 3x5 Managers II, LLC
    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Member

    /s/ Jay Schmelter

    Jay Schmelter
    RiverVest Venture Partners III, LLC
    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Member
    3x5 RiverVest Fund II-B, L.P.
    By:  

    3x5 RiverVest Partners II, LLC,

    its general partner

    By:  

    RiverVest 3x5 Managers II, L.P.,

    its member

    By:  

    RiverVest 3x5 Managers II, LLC,

    its general partner

    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Member
    RiverVest 3x5 Managers II, L.P.
    By:  

    RiverVest 3x5 Managers II, LLC,

    its general partner

    By:  

    /s/ John P. McKearn

      Name: John P. McKearn, Ph.D.
      Title:  Member

    /s/ John P. McKearn

    John P. McKearn, Ph.D.

    /s/ Thomas C. Melzer

    Thomas C. Melzer
     

     

    [Signature Page of Schedule 13D/A]

    Get the next $ALLK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALLK

    DatePrice TargetRatingAnalyst
    1/17/2024$6.00 → $1.50Buy → Hold
    Jefferies
    1/16/2024Overweight → Neutral
    Cantor Fitzgerald
    12/18/2023Mkt Perform → Outperform
    William Blair
    12/8/2023$9.00 → $6.00Buy
    Jefferies
    9/27/2023$11.00Mkt Outperform
    JMP Securities
    5/12/2023$6.00 → $9.00Hold → Buy
    Jefferies
    3/7/2023$22.00Overweight
    Piper Sandler
    9/12/2022$2.00Neutral → Underperform
    SMBC Nikko
    More analyst ratings

    $ALLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share

      SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. ("Allakos") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ( "Concentra") will acquire Allakos for $0.33 in cash per share of Allakos common stock ("Allakos Common Stock"). Allakos' Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Allakos shareholders and, following the unanimous recommendation of Allakos' Transaction Committee, has appro

      4/2/25 8:00:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

      SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024. Recent Allakos Events Reported topline data from the Phase 1 study of AK006 in patients with chronic spontaneous urticaria in January 2025.Announced in January 2025 that the Company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives. Cash Guidance Allakos ended the fourth qua

      3/12/25 4:02:00 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

      SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular

      2/11/25 11:30:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Allakos Inc.

      SC 13G - Allakos Inc. (0001564824) (Subject)

      11/12/24 9:50:12 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Allakos Inc.

      SC 13G/A - Allakos Inc. (0001564824) (Subject)

      7/8/24 4:32:41 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allakos Inc. (Amendment)

      SC 13G/A - Allakos Inc. (0001564824) (Subject)

      2/14/24 4:58:16 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    Financials

    Live finance-specific insights

    See more
    • Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

      – AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (NASDAQ:ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). "While AK006 was well tolerated, we are disappointed that the preclinical inhibitory effects observed did not translate to clinical benefit in patients with CSU. As a result, the Company has decided to discontinue further clinical developme

      1/27/25 7:00:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos Announces a Restructuring to Focus on Development of AK006

      Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteersa randomized, double-blind, placebo-controlled trial in patients with CSUa subcutaneous AK006 Phase 1 PK and bioavailability trial Management to host conference call and webcast today at 8:00 am E.T. SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 c

      1/16/24 7:02:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

      – Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK). "We are disappointed that these trials did not m

      1/16/24 7:00:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Allakos downgraded by Jefferies with a new price target

      Jefferies downgraded Allakos from Buy to Hold and set a new price target of $1.50 from $6.00 previously

      1/17/24 7:08:59 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Allakos from Overweight to Neutral

      1/16/24 1:35:19 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos upgraded by William Blair

      William Blair upgraded Allakos from Mkt Perform to Outperform

      12/18/23 6:44:17 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    Leadership Updates

    Live Leadership Updates

    See more
    • Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

      SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular

      2/11/25 11:30:00 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos Appoints Neil Graham to its Board of Directors

      SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan Pharmaceuticals Limited, Pharmaxis Limited and Zura Bio Limited. Among other experiences, Dr. Graham was the Vice President of Strategic Program Direction, Immunology and Inflammation at Regeneron Ph

      8/30/23 4:05:00 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

      SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc. Among other experiences, Dr. Sutherland held senior roles developing therapeutics at Translate Bio, Inc. as well

      8/2/23 4:05:00 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Bvf Partners L P/Il returned 16,312,872 shares to the company (SEC Form 4)

      4 - Allakos Inc. (0001564824) (Issuer)

      5/19/25 6:45:29 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Walker Paul Edward returned 6,147,260 shares to the company (SEC Form 4)

      4 - Allakos Inc. (0001564824) (Issuer)

      5/15/25 4:28:27 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Tomasi Adam returned 533,420 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Allakos Inc. (0001564824) (Issuer)

      5/15/25 4:08:04 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLK
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Allakos Inc.

      SCHEDULE 13G/A - Allakos Inc. (0001564824) (Subject)

      5/19/25 6:42:25 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Allakos Inc.

      SCHEDULE 13D/A - Allakos Inc. (0001564824) (Subject)

      5/19/25 4:15:11 PM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Allakos Inc.

      EFFECT - Allakos Inc. (0001564824) (Filer)

      5/19/25 12:15:05 AM ET
      $ALLK
      Biotechnology: Pharmaceutical Preparations
      Health Care